Search the GHTC website

Global health R&D delivers for Colorado

US government investment in global health R&D has delivered

Amount
$93.8 million
to Colorado research institutions
Jobs
1,400+ new jobs
for Colorado
Colorado's top USG-funded global health R&D institutions

Colorado's top USG-funded global health R&D institutions

Colorado State University
$58.3 million
University of Colorado at Denver
$27.2 million
University of Colorado at Boulder
$5.8 million
Precision Photonics Corporation (now part of IDEX Corporation)
$1.4 million
Colorado School of Mines
$1 million
Keystone Symposia on Molecular and Cellular Biology
$88 thousand
Colorado industry in global health R&D

Colorado industry in global health R&D

AstraZeneca
Location(s): Boulder
Endolytics
Location(s): Fort Collins
IDEX Corporation
Location(s): Denver
Mbio
Location(s): Boulder
Novartis
Location(s): Broomfield
Sandoz
Location(s): Broomfield

Colorado's top areas of global health R&D by USG funding

11.5%
HIV/AIDS
5.5%
Malaria
48.3%
Tuberculosis
2.7%
Diarrheal diseases
7.8%
Salmonella infections
19.7%
Neglected tropical diseases
Dengue
Helminths
Kinetoplastids
Leprosy
4.5%
Other
Bacterial pneumonia & meningitis
Global health R&D at work in Colorado

University of Colorado School of Medicine researchers discovered that a process that protects the body from autoimmune disease also blocks the production of antibodies against HIV-1, the most common cause of AIDS. The immune system normally suppresses these antibodies to keep them from targeting healthy tissues; the question now is whether temporarily halting this mechanism would allow generation of antibodies capable of neutralizing HIV-1 without harm to patients. The findings could help scientists develop a vaccine.

Footnotes
  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: PATH/Patrick McKern